Blue Arbor Technologies
Blue Arbor Technologies is a medical device company developing neuromuscular interfaces and robotic prosthetic control for people with limb loss.
Position in SVTR
Snapshot 2026-10-29- Startup SignalsRankedof 2,186new
- Life SciencesRankedof 230
- Medtech DeviceRankedof 44
- BCIRankedof 18
About
Blue Arbor Technologies is a medical device company developing neuromuscular interfaces and robotic prosthetic control for people with limb loss. Its RESTORE system uses implanted intramuscular electrodes to capture EMG signals and decodes them into prosthetic movement commands. RESTORE holds FDA Breakthrough Device Designation, and the company has a strategic partnership with Ottobock.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 1
Founders / team· 3
Funding history
- 2026-10-28Series A$11M
Investors · OttobockSource · bluearbortech.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Blue Arbor Technologies
Blue Arbor Technologies is a medical device company developing neuromuscular interfaces and robotic prosthetic control for people with limb loss. Its RESTORE system uses implanted intramuscular electrodes to capture EMG signals and decodes them into prosthetic movement commands. RESTORE holds FDA Breakthrough Device Designation, and the company has a strategic partnership with Ottobock.
Series A · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Coherence Neuro
Closed-loop brain-computer interface system SOMA, using a wireless implant to decode tumor electrical signals in real time and deliver personalized electrical stimulation to treat brain tumors and other cancers
Series A · 2026-10
— - Axoft
Implantable brain-computer interfaces using biomimetic materials, with flexible neural electronics for high-resolution neural recording and stimulation
Series A · $60M · 2026-05
$60M - Echo Neurotechnologies
Brain-computer interfaces that let patients with severe disabilities control devices with their thoughts via implanted electrodes
Series A · $50M · 2025-02
$50M
China
BusinessLatest roundTotal raisedDate- NeuroXess
Implantable flexible brain-computer interface systems (neural signal acquisition chips + decoding algorithms) for patients with neurological disorders
Series B · 2026-10
— - SiClink
Implantable brain-computer interfaces: in-house flexible neural electrodes and minimally invasive implantation with neural decoding/encoding algorithms, starting with visual restoration for visual impairment rehabilitation
— - BCI-Sonics
Non-invasive AI ultrasound brain-computer interface (transcranial focused ultrasound neuromodulation + multimodal brain reading and AI neural decoding)
Series A · $42M · 2026-09
$42M
Europe
BusinessLatest roundTotal raisedDate- MintNeuro
Imperial College London spinout developing composable chip modules for neural signal acquisition, electrical stimulation, on-chip processing and wireless transmission, for BCI and active implant makers
Undisclosed · 2026-10
— - Neurosoft Bioelectronics
Flexible, stretchable, non-penetrating brain-computer interfaces and neural electrodes to record/stimulate brain-surface activity
Seed · $20M · 2026-05
$20M - InBrain Neuroelectronics
Graphene-based brain-computer interface technology for neurological disorders such as Parkinson's disease.
Series B · $50M · 2024-11
$50M
Other / unspecified
BusinessLatest roundTotal raisedDate- Brain.space
Non-invasive brain monitoring platform with real-time neural data analysis
Series A · $11M · 2025-03
$11M - 脑思科技
Brain-computer interface electrodes and neural decoding systems
Angel · $10M · 2026-05
$10M - CustoMED
AI and 3D printing to produce patient-specific orthopedic surgical tools and implants
Seed · $6M · 2025-11
$6M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
40 Life Sciences deals in the last 24 months · 35 at a nearby stage · 33 in North America
Request intro →General Catalyst
40 Life Sciences deals in the last 24 months · 26 at a nearby stage · 36 in North America
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 12 at a nearby stage · 22 in North America
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in North America
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 15 in North America
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in North America
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.